London, Feb 13, 2026, 09:24 GMT — Regular session
Reckitt Benckiser Group plc RKT.L slipped 0.2% to 6,382 pence during Friday’s early London session. The consumer health and hygiene firm, which found some footing earlier this week, has seen its shares move between 6,322 and 6,416 pence so far—hovering close to the upper edge of its 52-week range.
Right now, investors are watching cash moves. Reckitt plans to issue a one-off special dividend of 235 pence per share on Feb. 20 to those on the books as of Jan. 30, according to a filing. Shares went ex-special dividend on Feb. 2, so anyone buying after that usually misses out on the payment.
Market watchers are looking for hints from Reckitt’s top brass ahead of earnings. CEO Kris Licht and CFO Shannon Eisenhardt are set to speak at the CAGNY investor event in Orlando on Feb. 19, according to the company. Their remarks will be webcast from 1500 to 1545 GMT.
Global equities are seeing more turbulence, and that’s put defensive stocks back in focus. “The prevailing tone in markets is a rotation toward more defensive areas of the equity market,” said Chris Weston, head of research at Pepperstone, highlighting fresh risk-off moves. Reuters
The FTSE 100 slipped 0.7% in London on Thursday, with a wave of caution dampening gains made by some individual stocks. Fresh data put Britain’s economic growth at just 0.1% for the fourth quarter, as market players continued to grapple with the path ahead for rate cuts. Unilever shares drew attention, too, after the group pointed to sluggish sales growth in the U.S. and Europe for 2026, putting consumer goods in the spotlight.
Shares of Reckitt finished Thursday at 6,394 pence, gaining 1.27% for the day, market data showed. Since the early-February dividend and share consolidation mechanics, the stock’s trading range has narrowed.
Not much on the company news front so far this week. For Reckitt, the most recent regulatory filings out of London trace back to Feb. 2, covering items like the ongoing share buyback and other corporate moves.
Risks linger. Reckitt remains exposed to ongoing U.S. litigation over its Mead Johnson infant-formula business—a headline risk that tends to jolt sentiment when court decisions drop.
Reckitt has pegged March 5 for its full-year results, with an investor presentation set for 0830 GMT in London, the company said.
